Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about UbiVac, Janssen collaborates to develop & test vaccine to intercept oral cancer
UbiVac, a privately held clinical stage immuno-oncology company, collaborate with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator.
- Read more about Stress in Infants Resort to Habits
In adults, previous studies have suggested that stress promotes habits and reduces cognitive flexibility. Psychologists from Germany's Ruhr University Bochum have revealed that the same is true for infants. While under stress, even infants are inclined to resort to habits, rather than try out new things. The findings were published in PNAS.

[adsense:336x280:8701650588]
2 October 2015

Positive Relationship with Siblings reduce Risky Behavior in Adolescence

A new study revealed that Older siblings who had positive relationships with their younger siblings have fewer depressive symptoms and lowest levels of risky behaviors. Overall, the researchers observed that whereas siblings with negative relationships engaged in more risky behaviors. The study appeared in the International Journal of Behavioral Development.
- Read more about NuMedii develop research alliance with Allergan to find new way to treat psoriasis
NuMedii, Inc. announced the formation of a research alliance with Allergan to explore new therapeutic options for the potential treatment of psoriasis. NuMedii has already generated multiple lead compounds/candidates by utilising its data intelligence technology for psoriasis, which will be the focus of the research alliance with Allergan.
- Read more about Novartis's secukinumab confirmed significant efficacy in patients with psoriatic arthritis
Novartis's pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in the New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) inhibitor to demonstrate efficacy in a Phase III study in patients with active PsA, a painful, debilitating condition causing inflammation of joints and skin. PsA is part of a family of long-term diseases impacting joints, known as spondylorarthritis.
- Read more about Pfizer Partners with Breast Cancer Leaders to Chronicle the lives of women with metastatic breast cancer through the Lenses of Prominent Photographers
Pfizer Inc., in partnership with five leading breast cancer advocacy organizations, today announced the next chapter of the Breast Cancer: A Story Half Told initiative, launched in 2014 to identify public misperceptions and gaps in knowledge surrounding metastatic breast cancer (MBC), the most advanced form of breast cancer. Research conducted as part of this initiative revealed that the majority of Americans (60%) reported they know little to nothing about MBC.1The new chapter aims to address this lack of understanding through the perspectives of women living with MBC, as chronicled by prominent photographers.
- Read more about Scientists developed insulin-producing cells in vivo
A new technique to produce cells with insulin-secretion capabilities has been developed, according to research presented at the 54th Annual European Society for Paediatric Endocrinology Meeting. The technique could be further developed to be used in the transplantation for patients with type 1 diabetes.
- Read more about HIV patients should be included in early clinical trials of anti-TB drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide, yet the majority of these patients are excluded from the early stages in the development of new, anti-tuberculosis drugs, according to findings presented today (29 September, 2015) at the European Respiratory Society's International Congress 2015.
- Read more about Atezolizumab set to change refractory lung cancer treatment
Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck’s comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.1
- Read more about Nivolumab improves the proportion of lung cancer patients alive after more than a year
Updated results from the CheckMate 057 phase III clinical trial, show that nivolumab continues to show an overall survival benefit compared to docetaxel in patients with non-squamous non-small cell lung cancer